Publications & Reports

Targeting B cells in treatment of autoimmunity.

Franks SE, Getahun A, Hogarth PM, Cambier JC
Department of Immunology and Microbiology, University of Colorado School of Medicine, Denver, CO, USA.


B cells have emerged as effective targets for therapeutic intervention in autoimmunities in which the ultimate effectors are antibodies, as well as those in which T cells are primary drivers of inflammation. Proof of this principle has come primarily from studies of the efficacy of Rituximab, an anti-CD20 mAb that depletes B cells, in various autoimmune settings. These successes have inspired efforts to develop more effective anti-CD20s tailored for specific needs, as well as biologicals and small molecules that suppress B cell function without the risks inherent in B cell depletion. Here we review the current status of B cell-targeted therapies for autoimmunity.

Link to publisher’s web site

Link to full text on PubMed Central


  • Journal: Current Opinion in Immunology
  • Published: 05/10/2016
  • Volume: 43
  • Pagination: 39-45